Association Between Buprenorphine for Opioid Use Disorder and Mortality Risk.

ABSTRACT:

Introduction

Veterans with opioid use disorder have an increased risk of suicide and overdose compared with the general population. Buprenorphine, a U.S. Food and Drug Administration-approved medication to treat opioid use disorder, has shown benefits, including decreased risk of illicit drug use and overdose. This study assesses the mortality outcomes with buprenorphine pharmacotherapy among Veterans up to 5 years from treatment initiation.

Methods

This was a retrospective cohort study of Veterans receiving buprenorphine (2008-2017) across any Veterans Health Administration facility. Buprenorphine pharmacotherapy was evaluated as a time-varying covariate. The primary outcome was death up to 5 years from treatment initiation by suicide and overdose combined; secondary outcom

SUBMITTER: Vakkalanka P 

PROVIDER: S-EPMC8384722 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature